At the corporate strategic development level, in addition to establishing a development platform for drugs for the treatment of diseases such as ophthalmic diseases, the company also takes scientific research institutes, hospital clinical researchers, pharmaceutical companies, etc. as its main potential customers, and actively prepares to launch external service projects, including: screening and licensing of superior cell lines (cell line screening, cell line improvement and library establishment, selection of indications, functional cell differentiation, small animal experiments); outsourcing services for experimental technologies, customized production services for cell lines; outsourcing services for the directed differentiation of iPSCs and the preparation of organoids, as well as experiments such as drug screening, function and toxicology based on iPSC technology; and the establishment of iPS cell banks for different gene mutations or disease types.
